BioNTech has agreed to acquire CureVac in an all-stock deal valued around $1.25 billion, marking a strategic expansion of its mRNA platforms for cancer immunotherapy. The acquisition focuses primarily on CureVac’s research capabilities and manufacturing site in Germany, positioning BioNTech to enhance its oncology pipeline including PD-L1 bispecific antibodies and mRNA therapies. CureVac’s rare cancer vaccine candidates are noted but not the centerpiece of the deal. The move intensifies competition and innovation in mRNA-driven cancer treatment development.